Avedro Receives CE Mark for Mosaic System, Announces CEO Transition
Avedro has received CE Mark clearance for its Mosaic System, according to a company news release. The Mosaic System has the potential to provide nonsurgical improvement for low myopia with the Photorefractive Intrastromal Cross-linking (PiXL) procedure. The Mosaic system is now commercially available outside the United States.
Avedro also announced that, following the completion of a recent US$32 million round of financing, David Muller resigned as Chief Executive Officer in order to pursue other opportunities. “On behalf of the Board and all the Avedro employees, I want to thank David for his tireless efforts,” Gil Kliman, MD, Interwest General Partner and member of the Avedro Board of Directors, said in the news release. “Ophthalmologists around the world have David to thank for the advances in corneal crosslinking that Avedro researched, developed, and commercialized around the world under his leadership.”
Brian Roberts will lead the company while the board conducts a search for Avedro’s next CEO.
Refractive Surgeons More Likely than the General Population to Undergo Laser Vision Correction
The Refractive Surgery Alliance (RSA) announced that, based on data published in the Journal of Cataract & Refractive Surgery,1 nearly two-thirds (62.6%) of refractive surgeons who were candidates for refractive surgery have had their vision corrected. According to a news release, the study also reported that more than 91% of all refractive surgeons recommend refractive surgery to their immediate family members.
“Technical advances have made refractive surgery not only safe but extremely accurate,” Guy M. Kezirian, MD, MBA, Founder of the RSA and lead author of the study, said in the news release. “The fact that the people who know the most about refractive surgery are having the surgery performed on themselves and their families speaks volumes about the benefits of this procedure.”
The 22-question Global Survey on Refractive Surgery in Refractive Surgeons was sent by email to 250 ophthalmologists randomly selected from a database of 2,441 ophthalmologists known to have performed laser vision correction (LVC) at some point in the past decade. Responses were solicited by email with subsequent telephone reminders to nonresponders.
According to the study, responses were received from 248 (99.2%) of 250 queried individuals, of whom 232 (92.8%) met the protocol criteria of currently working as refractive surgeons. Of the 232 participants, 161 (69.4%) reported that they had refractive errors potentially amenable to treatment with LVC, not including presbyopia. Of the 161 ophthalmologists with treatable refractive errors, 54 (33.5%) reported they were not candidates for LVC for a variety of reasons, and 107 (66.5%) reported they were candidates for LVC. Of the LVC candidates, 62.6% reported that they had undergone an LVC procedure. Of the overall 232 subjects, more than 90% recommend LVC for adult members of their immediate family.
“Prospective surveys that define the study population before they present the questions are scientifically valid because they eliminate response bias,” Greg Parkhurst, MD, incoming RSA president and study author, said in the news release. “This approach is far more valuable than using results from people who were motivated to respond to a poll. The high response rate makes this extremely reliable.”
The study shows refractive surgeons are more than four times more likely to have refractive surgery than the general population. “Many patients just don’t know about refractive surgery,” study author Jason P. Brinton, MD, said in the news release. “There is a need for public education about the benefits. Several recent studies have shown that refractive surgery generally provides better vision than glasses or contact lenses, is much safer than contact lenses and is far cheaper over time. We need to get the word out.”
1. Kezirian GM, Parkhurst GD, Brinton JP, Norden RA. Prevalence of laser vision correction in ophthalmologists who perform refractive surgery. J Cataract Refract Surg. 2015;41(9):1826-1832.
Refractive Surgery Pioneer Lee Nordan, MD, passes away
Lee T. Nordan, MD, an internationally recognized authority on refractive surgery, died December 22 at the age of 69.
1. North County Laser Eye Associates. http://www.nclasik.com/html/meet.html#lee. Accessed December 22, 2015.
2. Nordan L. 5 Questions with Lee T. Nordan, MD. Cataract & Refractive Surgery Today. July 2011: 74.
Dry Eye Disease May Not Worsen Over Time in Most Patients
Dry eye disease (DED) does not necessarily worsen over time in most patients, a retrospective survey-based study in Ophthalmology suggests.1
Jeffrey P. Leinert, MS, of the Harvard T. H. Chan School of Public Health in Boston, and colleagues analyzed the medical records of 398 men and 386 women who reported a diagnosis of DED and responded to a questionnaire about change in disease since diagnosis. Men included in the study ranged in age from 60.2 to 97.3 years and had DED an average of 10.5 years, and women ranged in age from 61.2 years to 89.9 years with an average disease duration of 14.5 years.
The investigators developed three subscales using factor analysis of questionnaire responses: ocular surface symptoms, vision-related symptoms, and social impact. They examined correlates of worsening on each subscale, obtained medical records from a subset of 261 study participants, and examined changes in clinical signs of DED over time.
The average duration of DED was 10.5 years. Worsening was reported by 24% of patients for ocular surface symptoms, 29% for vision-related symptoms, and 10% for social impact. Factors associated with worsening on at least two of three subscales included a previous report of severe DED symptoms (OR, 2.17 for ocular surface symptoms; OR, 2.35 for vision-related symptoms), spending more than US$20 per month on DED treatments (OR, 1.80 for ocular surface symptoms; OR, 1.99 for vision-related symptoms), history of blepharitis or meibomian gland dysfunction (OR, 1.57 for vision-related symptoms; OR, 2.12 for social impact), and use of systemic beta-blockers (OR, 1.62 for ocular surface symptoms; OR, 1.84 for vision-related symptoms; OR, 1.86 for the social impact of DED).
Presence of corneal staining based on review of medical records was associated with use of level 2 or higher DED treatments (OR, 1.54; CI, 1.01–2.36), a previous report of severe DED symptoms (OR, 1.79; CI, 1.07–3.00), having a tear breakup test performed (OR, 2.73; CI, 1.72–4.36), and having blepharitis or meibomian gland dysfunction (OR, 0.59; CI, 0.35–0.98).
“A proportion of patients with DED experience worsening over time, tending to report with more severe symptoms earlier in the disease,” the study authors wrote. “Forthcoming data on the natural history of DED from prospective studies should help clarify some of the limitations of this retrospective study.”
1. Leinert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term natural history of dry eye disease from the patient’s perspective [published online ahead of print November 21, 2015]. Ophthalmology. doi:http://dx.doi.org/10.1016/j.ophtha.2015.10.011.
Geuder Expands Product Range With Sterile Trephine and Cornea Punches
Geuder has expanded its trephine portfolio with sterile single-use trephines, single-use vacuum trephines, sterile single-use trephine punches, and single-use vacuum trephine punches from SurgiStar, the company said in a
According to Geuder, the portfolio of different diameters, from 2.5 mm up to 18 mm in steps of 0.25 mm, and different versions of long and short trephines, radial and vacuum trephines, trephine punches, and vacuum trephine punches complete the product range.
Leica Microsystems Launches Ophthalmic Microscope Platform
Lecia Microsystems launched the Proveo 8, the core of a new ophthalmic microscope platform for cataract and vitreoretinal surgeries, according to a news release.
The Proveo 8 is equipped with breakthrough innovations such as FusionOptics and CoAx4 Illumination. FusionOptics is an exclusive technology from Leica that combines 40% increased depth of field with high resolution, providing surgeons with a texture-rich image from the edges of a detached membrane to the periphery of the retina without refocusing. Another Leica exclusive feature, CoAx4 Illumination, reportedly delivers light through four individual beam paths and allows for adjustment of the illumination diameter. This results in a constant red reflex and high-contrast visualization without compromise for the main surgeon or the assistant.
The Proveo has been designed to easily integrate innovative surgical technologies such as IOL guidance systems for precise IOL positioning, intraoperative OCT to observe ocular tissue microstructures, or three-dimensional heads-up surgery.
–Compiled by Steve Daily, Executive Editor, News;
and Callan Navitsky, Senior Editor
Q&A: Allergan President and CEO Brent Saunders on the Future of Eye Care After Pfizer Merger
By Stephen Daily, Executive Editor, News
Warning Signs May Precede Cardiac Arrest
Sudden cardiac arrest may not be as sudden as it is widely perceived to be, with warning symptoms occurring in a large percentage of patients.
No-Helmet Practices May Reduce Concussion Risk
Although seemingly counterintuitive, a new strategy that involves not using helmets during football practice may help reduce concussions on the field, a study suggests.
ALS Toxic Protein Study Opens New Door for Drug Discovery
A study provides the first evidence-based description of a type of protein clump thought to play an important role in amyotrophic
lateral sclerosis (ALS) by killing the
nerve cells that control movement.
Patients With Dementia Benefit from Family Visits
The Alzheimer’s Society said family visits stimulate feelings of happiness, comfort, and security in patients with dementia, as they can still hold an emotional memory.
High Amounts of Dietary Sugar May Increase Breast Cancer Risk
An animal study suggests that high amounts of dietary sugar may increase the risk of breast cancer and metastasis, due to sugar’s impact on inflammatory pathways.